Humoral hypercalcemia of malignancy

Humoral hypercalcemia of malignancy is a systemic metabolic paraneoplastic syndrome that occurs in patients with advanced cancers, most commonly squamous cell carcinomas, renal cell carcinoma, ovarian cancer, and breast carcinoma

Humoral hypercalcemia of malignancy is a systemic metabolic paraneoplastic syndrome that occurs in patients with advanced cancers, most commonly squamous cell carcinomas, renal cell carcinoma, ovarian cancer, and breast carcinoma

It affects the skeletal and renal systems through the tumor-driven secretion of circulating factors, overwhelmingly parathyroid hormone-related protein (PTHrP), without requiring direct skeletal metastases

It affects the skeletal and renal systems through the tumor-driven secretion of circulating factors, overwhelmingly parathyroid hormone-related protein (PTHrP), without requiring direct skeletal metastases

It affects the skeletal and renal systems through the tumor-driven secretion of circulating factors, overwhelmingly parathyroid hormone-related protein (PTHrP), without requiring direct skeletal metastases

Clinically and pathophysiologically, circulating PTHrP binds to parathyroid hormone receptors, triggering profound osteoclastic bone resorption and stimulating renal tubular calcium reabsorption while promoting phosphate wasting, which leads to severe, often life-threatening elevations in serum calcium

Clinically and pathophysiologically, circulating PTHrP binds to parathyroid hormone receptors, triggering profound osteoclastic bone resorption and stimulating renal tubular calcium reabsorption while promoting phosphate wasting, which leads to severe, often life-threatening elevations in serum calcium